1. Executive Summary
1.1 China: Pharmaceutical Market Review
1.2 Contents of this Report
1.3 Research and Analysis Methods
2. Chinese Pharmaceutical Market: An Overview
2.1 China: National Overview
2.1.1 China's Rise as an Economic Superpower
2.2 From Maoism to Market: Chinese Healthcare Since World War II
2.2.1 Socialised Healthcare
2.2.2 Developments Since 1992
2.2.3 Investment, But Healthcare Disparities Remain
2.3 The Rise of the Chinese Pharmaceutical Market
2.3.1 Picking up the Tab
2.4 Healthy China 2020: 'Unprecedented in Human History'
2.4.1 Achievements and Potential of the Healthy China 2020 Initiative
2.5 Demography and Disease Burden in China
2.5.1 The Ageing Population
2.5.2 Obesity in China
2.5.3 Stroke, Heart Disease and Diabetes
2.5.4 Cancer and Respiratory Diseases
2.5.5 Communicable Diseases
2.6 Other Aspects of the Chinese Market
3. The Chinese Pharmaceutical Market, 2012-2022
3.1 Chinese Pharmaceutical Market: Forecast, 2012-2022
3.2 The Product Mix in China, 2010
3.3 The Product Mix in China, 2012-2022
3.4 Prescribed Patented Brands: Forecast, 2012-2022
3.4.1 Drivers and Restraints for Patented Prescription Drugs
3.5 Prescribed Generics: Forecast, 2012-2022
3.5.1 Drivers and Restraints for Prescribed Generics
3.6 OTC Products: Forecast, 2012-2022
3.6.1 Drivers and Restraints for OTC Products
3.7 TCM Products: Forecast, 2012-2022
3.7.1 Drivers and Restraints for TCM Products
4. Leading Therapeutic Areas in the Chinese Market, 2012-2022
4.1 Anti-Infectives Market, 2012-2022
4.1.1 Antibiotics: China's Drugs of Choice
4.1.2 Antivirals: a Growth Area
4.2 Cancer Treatments Market, 2012-2022
4.2.1 Small Molecules Dominate the Chinese Cancer Drug Market
4.3 Cardiovascular/Cerebrovascular Market, 2012-2022
4.3.1 Anti-Aggregants, Statins and Vasotherapeutics
4.4 Alimentary and Metabolic Diseases Market, 2012-2022
4.4.1 Antiulcerants and Diabetes Treatments
4.5 Central Nervous System Diseases Market, 2012-2022
4.5.1 Pain Relief
4.5.2 Anti-Depressants
4.5.3 Neurodegenerative Diseases
4.6 Vaccines Market, 2012-2022
4.6.1 Opportunities and Challenges in Vaccines
4.7 Other Therapeutic Classes Market, 2012-2022
5. China as a Pharmaceutical Hub, 2012-2022
5.1 China as a Manufacturing Hub
5.1.1 China's API Export Market
5.1.2 Contract Manufacturing Organisations: Beyond APIs
5.2 China as a Research Hub
5.2.1 Clinical Trials in China
5.2.2 The Rise of China's Contract Research Organisations
5.3 China as a Biotechnology Hub
5.3.1 Leading the Way in Biosimilars
5.3.2 Biomarkers and Genomic Sequencing
5.3.3 Stem Cells in China
5.3.4 Other Regenerative Medicine in China
5.4 China as a Pharmaceutical Hub: Conclusions
6. Key Domestic Players in the Chinese Market, 2012
6.1 Fragmentation and Consolidation Among Chinese Companies
6.2 Summary of Leading Domestic Companies
6.3 China National Pharmaceutical Corporation (Sinopharm)
6.4 China National Biotec Group (CNBG)
6.5 WuXi AppTec
6.6 CSPC Pharmaceutical Group
6.7 Beijing Pharmaceutical Group
6.8 Shanghai Pharmaceutical Group (SPGC)
6.9 Yangtze River Pharmaceutical Group
6.10 Tianjin Pharmaceuticals Group Corporation (TJPC)
6.11 Taiji Group
6.12 C&O Pharmaceutical Technology Holdings
6.13 Harbin Pharmaceutical Group Holding Company
6.14 Guangzhou Pharmaceutical Holdings
6.15 Sinovac Biotech (Beijing Kexing Bioproducts)
6.16 Tongrengtang Pharmaceutical
6.17 Buchang Pharmaceutical
6.18 Northeast Pharmaceutical Group (NEPG)
6.19 China Nepstar Chain Drugstore
6.20 Zhejiang Huahai Pharmaceuticals
6.21 Hangzhou Zhongmei Huadong Pharmaceutical
6.22 Hualan Biological Engineering
6.23 China Sky One Medical
6.24 Zensun (Shanghai) Sci & Tech
6.25 Ascletis
6.26 Shangdong Dong-E-E-Jiao
6.27 Mindray Medical International and China Medical Technologies
7. Key Multinational Players in the Chinese Market, 2012
7.1 Bayer Schering
7.2 AstraZeneca
7.3 Pfizer
7.4 Sanofi
7.5 Roche
7.6 Novartis
7.7 GlaxoSmithKline
7.8 Merck & Co.
7.9 Novo Nordisk
7.10 Eli Lilly
7.11 Abbott Laboratories
7.12 Johnson & Johnson
7.13 Bristol-Myers Squibb
7.14 Teva Pharmaceutical Industries
7.15 Takeda
8. The Chinese Pharma Market: Qualitative Analysis
8.1 Strengths: Government Investment Will Further Expand this Dynamic Market
8.2 Weaknesses: IP and Regulatory Challenges Remain
8.3 Opportunities: The Scramble for China
8.4 Threats: A House Built on Sand?
9. Research Interviews
9.1 Interview with Dr Derek Lowe, Drug Discovery Expert
9.1.1 On the Rising Cost of Outsourcing Research to China
9.1.2 On Building Relationships in the Chinese Market
9.1.3 On Prospects for Western Brands in the Chinese Market
9.1.4 On IP Protection and Safety Concerns in China
9.1.5 On the Role of the Chinese State in the Pharmaceutical Market
9.1.6 On Biotechnology and the Chinese Research Culture
9.1.7 On Chinese Biosimilar Manufacturing
9.2 Interview with Dr Jean-Pierre Wery, President, Crown Bioscience, China
9.2.1 Contract Research Services Offered by Crown Bioscience
9.2.2 On Technological Platforms and Animal Models Relevant to Biomarkers
9.2.3 On the Range of Therapeutic Areas Covered by Crown Bioscience
9.2.4 On Translational Medicine and Patient Stratification
9.2.5 On the Future for Crown Bioscience and Other CROs
10. Conclusions
10.1 The Chinese Pharma Market Will Continue to Grow Rapidly
10.2 Treatments for Chronic Diseases Will Challenge the Anti-Infectives Sector
10.3 China Will Continue to Grow as a Focus for the Multinational Industry
10.4 China is Set to be the Most Important Pharmaceutical Market, Despite Weaknesses
List of Tables
Table 2.1 Causes of Mortality in China, 2002
Table 3.1 Chinese Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), 2010-2015
Table 3.2 Chinese Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), 2016-2022
Table 3.3 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2010
Table 3.4 Chinese Pharmaceutical Market Breakdown by Sector: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 3.5 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2015
Table 3.6 Chinese Pharmaceutical Market Breakdown by Sector: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 3.7 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2022
Table 3.8 Prescribed Patented Brands Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 3.9 Prescribed Patented Brands Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 3.10 Prescribed Generics Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 3.11 Prescribed Generics Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 3.12 OTC Products Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 3.13 OTC Products Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 3.14 TCM Products Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 3.15 TCM Products Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 4.1 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2010
Table 4.2 Chinese Pharmaceutical Market Breakdown by Therapeutic Class: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.3 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2015
Table 4.4 Chinese Pharmaceutical Market Breakdown by Therapeutic Class: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 4.5 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2022
Table 4.6 Anti-Infectives Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.7 Anti-Infectives Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 4.8 Oncology Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.9 Oncology Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 4.10 Cardiovascular/Cerebrovascular Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.11 Cardiovascular/Cerebrovascular Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 4.12 Alimentary/Metabolic Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.13 Alimentary/Metabolic Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 4.14 CNS Diseases Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.15 CNS Diseases Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 4.16 Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.17 Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 4.18 Other Therapeutic Classes Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015
Table 4.19 0ther Therapeutic Classes Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022
Table 8.1 Strengths and Weaknesses in the Chinese Pharma Market, 2012-2022
Table 8.2 Opportunities and Threats in the Chinese Pharma Market, 2012-2022
List of Figures
Figure 2.1 Causes of Mortality in China, 2002
Figure 3.1 Chinese Pharmaceutical Market: Revenues ($bn), 2010-2015
Figure 3.2 Chinese Pharmaceutical Market: Revenues ($bn), 2016-2022
Figure 3.3 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2010
Figure 3.4 Chinese Pharmaceutical Market Breakdown by Sector: Revenues ($bn), 2010-2015
Figure 3.5 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2015
Figure 3.6 Chinese Pharmaceutical Market Breakdown by Sector: Revenues ($bn), 2016-2022
Figure 3.7 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2022
Figure 3.8 Prescribed Patented Brands Market: Revenues ($bn), 2010-2015
Figure 3.9 Prescribed Patented Brands Market: Revenues ($bn), 2016-2022
Figure 3.10 Prescribed Generics Market: Revenues ($bn), 2010-2015
Figure 3.11 Prescribed Generics Market: Revenues ($bn), 2016-2022
Figure 3.12 OTC Products Market: Revenues ($bn), 2010-2015
Figure 3.13 OTC Products Market: Revenues ($bn), 2016-2022
Figure 3.14 TCM Products Market: Revenues ($bn), 2010-2015
Figure 3.15 TCM Products Market: Revenues ($bn), 2016-2022
Figure 4.1 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2010
Figure 4.2 Chinese Pharmaceutical Market Breakdown by Therapeutic Class: Revenues ($bn), 2010-2015
Figure 4.3 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2015
Figure 4.4 Chinese Pharmaceutical Market Breakdown by Therapeutic Class: Revenues ($bn), 2016-2022
Figure 4.5 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2022
Figure 4.6 Anti-Infectives Market: Revenues ($bn), 2010-2015
Figure 4.7 Anti-Infectives Market: Revenues ($bn), 2016-2022
Figure 4.8 Oncology Market: Revenues ($bn), 2010-2015
Figure 4.9 Oncology Market: Revenues ($bn), 2016-2022
Figure 4.10 Cardiovascular/Cerebrovascular Market: Revenues ($bn), 2010-2015
Figure 4.11 Cardiovascular/Cerebrovascular Market: Revenues ($bn), 2016-2022
Figure 4.12 Alimentary/Metabolic Market: Revenues ($bn), 2010-2015
Figure 4.13 Alimentary/Metabolic Market: Revenues ($bn), 2016-2022
Figure 4.14 CNS Diseases Market: Revenues ($bn), 2010-2015
Figure 4.15 CNS Diseases Market: Revenues ($bn), 2016-2022
Figure 4.16 Vaccines Market: Revenues ($bn), 2010-2015
Figure 4.17 Vaccines Market: Revenues ($bn), 2016-2022
Figure 4.18 Other Therapeutic Classes Market: Revenues ($bn), 2010-2015
Figure 4.19 0ther Therapeutic Classes Market: Revenues ($bn), 2016-2022